Vaporized Nicotine Products for Smoking Cessation Among People Experiencing Social Disadvantage
- 1 August 2025
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (8) , 1085-1094
Abstract
Vaporized nicotine products (VNPs) are more effective than nicotine replacement therapy (NRT) for smoking cessation in general populations, but their effectiveness among low socioeconomic groups is largely unknown. To examine whether VNPs are more effective than NRT for smoking cessation among people experiencing social disadvantage. Two-group, open-label, randomized trial with blinded outcome ascertainment. (Australian New Zealand Clinical Trials Registry ACTRN12621000076875). Australia, between March 2021 and December 2022. 1045 adults who smoked daily, were willing to quit smoking, and were receiving a government pension/allowance (proxy for social disadvantage). Participants were randomly assigned (1:1) to either a free 8-week supply of NRT or VNPs, and all participants received text-message support. The primary outcome was 6-month continuous smoking abstinence verified using a carbon monoxide breath test at 7-month follow-up. Analysis included randomly assigned participants in accordance with Russell Standard criteria and the intention-to-treat principle. Among 1045 randomly assigned participants, 866 (82.9%) completed final follow-up. The verified 6-month continuous abstinence rate was 9.6% (50 of 523) in the NRT group and 28.4% (148 of 522) in the VNP group (posterior risk difference estimate, 18.7% [95% credible interval, 14.1% to 23.3%]; >99% posterior probability that VNP is superior). Self-reported adverse events occurred less frequently in the VNP group (355 events among 237 participants) compared with the NRT group (442 events among 278 participants; incident rate ratio, 0.75 [95% CI, 0.65 to 0.88]; P < 0.001). Biochemical verification method tested short-term exposure to cigarette smoke. Findings indicate that VNPs were more effective than NRT for smoking cessation in this population. Given the challenges for cessation among these socially disadvantaged populations, VNPs present a promising treatment option for this priority group. Australian National Health and Medical Research Council.Keywords
This publication has 30 references indexed in Scilit:
- Electronic cigarettes for smoking cessationCochrane Database of Systematic Reviews, 2025
- ELECTRONIC NICOTINE PRODUCT USE IS ASSOCIATED WITH INCIDENT HEART FAILURE - THE ALL OF US RESEARCH PROGRAMJACC, 2024
- The role of flavored electronic nicotine delivery systems in smoking cessation: A systematic reviewDrug and Alcohol Dependence Reports, 2023
- Electronic cigarettes for smoking cessationCochrane Database of Systematic Reviews, 2022
- Effectiveness of a Vaping Cessation Text Message Program Among Young Adult e-Cigarette UsersJAMA Internal Medicine, 2021
- A Randomized Trial of E-Cigarettes versus Nicotine-Replacement TherapyNew England Journal of Medicine, 2019
- Nicotine replacement therapy versus control for smoking cessationCochrane Database of Systematic Reviews, 2018
- Initial ratings of different types of e-cigarettes and relationships between product appeal and nicotine deliveryPsychopharmacology, 2018
- Relapse prevention interventions for smoking cessationCochrane Database of Systematic Reviews, 2013
- Discontinuation of Nicotine Replacement Therapy Among Smoking-Cessation AttemptersAmerican Journal of Preventive Medicine, 2008